Preclinical Biomarker Analysis Services
Integrated, translational biomarker solutions for preclinical research. From discovery to longitudinal validation using advanced multiplex and molecular platforms.
Biomarker analysis can be implemented at every stage of drug research and development, using a wide range of biological matrices including cell cultures, serum, plasma, urine, tissue extracts, and more. These analyses enable the identification of biomarker patterns associated with disease progression, therapeutic response, as well as metabolic and toxicity profiles.
NEPHRIX Biosolutions offers integrated biomarker services covering discovery, gene expression, signaling and metabolite assessment. Beyond conventional technics such as Western blot and ELISA, our services rely on advanced singleplex and multiplex platforms, including qRT-PCR, Meso Scale Discovery (MSD) multi-array technology, Luminex assays, flow cytometry, ensuring robust, sensitive, and translationally relevant data.
Detection Platforms
- Luminex multiplex assays – up to 50+ analytes per sample
- Meso Scale Discovery (MSD) ultra-sensitive multi-array electrochemiluminescence
- qRT-PCR & miRNA profiling – gene expression & microRNA detection
- Flow cytometry & CBA – cell phenotyping & cytokine bead arrays
- ELISA & Western blot – validated singleplex endpoints
Biomarker Categories & Key Applications
Our biomarker platform covers the full spectrum of renal disease biology, from classical functional endpoints to emerging precision medicine targets.
| Biomarker Category | Specific Biomarkers | Key Applications |
|---|---|---|
| Renal Function Markers | Serum creatinine, Blood urea nitrogen (BUN), Cystatin C | • GFR estimation • Early CKD staging • Drug nephrotoxicity monitoring |
| Markers of Kidney Damage | Albuminuria, Proteinuria, KIM-1, NGAL | • AKI detection • Glomerular/tubular injury assessment • Therapeutic efficacy tracking |
| Inflammatory Markers | IL-6, TNF-α, MCP-1, IL-1β | • Immune-mediated nephritis profiling • Inflammatory flare monitoring • Biomarker-guided immunosuppression |
| Fibrosis Markers | TGF-β, Collagen IV, Fibronectin, α-SMA | • Fibrosis progression scoring • Anti-fibrotic drug validation • CKD prognosis |
| Custom Biomarker Assays | Biomarker Assays Client-specified targets (novel proteins, metabolites) | • Mechanistic MoA studies • First-in-class therapeutic development • Companion diagnostic development |